Belantamab Mafodotin Induces Durable Response When Combined With Pom-Dex, Despite Ocular Effects | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. The anti-BCMA belantamab mafodotin (belamaf), plus pomalidomide and dexamethasone (Pd), produced durable responses in patients with relapsed or refractory multiple myeloma (MM), but adverse ocular effects were common though manageable, researchers reported in a new paper in Nature Medicine. The results of the phase I/II ALGONQUIN trial — mainly intended to evaluate dose-limiting toxicities, identify a recommended phase II dose,